Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series

Journal of Autoimmunity

Volumn 57, Issue , 2015, Pages 24-29

  Roberts, Darren M ^a,b   Jones, Rachel B ^a   Smith, Rona M ^a   Alberici, Federico ^a,c   Kumaratne, Dinakantha S ^a   Burns, Stella ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Autoimmune; Hypogammaglobulinemia; Infection; Replacement therapy; Rituximab; Vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; LUPUS VULGARIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; SYSTEMIC VASCULITIS; VASCULITIS; AGAMMAGLOBULINEMIA; AUTOIMMUNE DISEASES; BLOOD; CHEMICALLY INDUCED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922950105     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.11.004     Document Type: Article

References (32)

1. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
2. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEngl J Med 2004, 350:2572-2581.
3. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. NEngl J Med 2010, 363:221-232.
4. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. NEngl J Med 2010, 363:211-220.
5. Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
6. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013, 65:2441-2449.
7. Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013, 13:106-111.
8. Besada E., Koldingsnes W., Nossent J.C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford) 2013, 52:2041-2047.
9. Venhoff N., Effelsberg N.M., Salzer U., Warnatz K., Peter H.H., Lebrecht D., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012, 7. e37626.
10. Makatsori M., Kiani-Alikhan S., Manson A.L., Verma N., Leandro M., Gurugama N.P., et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 2014, 107:821-828.
11. Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. JAllergy Clin Immunol 2010, 125. 1354-60 e4.
12. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001, 135:165-174.
13. Abdou N.I., Greenwell C.A., Mehta R., Narra M., Hester J.D., Halsey J.F. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 2009, 149:267-274.
14. Lingman-Framme J., Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs 2013, 73:1307-1319.
15. Furst D.E. Serum immunoglobulins and risk of infection: how low can you go?. Semin Arthritis Rheum 2009, 39:18-29.
16. Curtis J.R., Yang S., Patkar N.M., Chen L., Singh J.A., Cannon G.W., et al. Risk of hospitalized bacterial infections associated with biologic treatment among U.S. Veterans with rheumatoid arthritis. Arthritis Care Res 2014, 66:990-997.
17. Looney R.J., Srinivasan R., Calabrese L.H. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008, 58:5-14.
18. Quinti I., Soresina A., Guerra A., Rondelli R., Spadaro G., Agostini C., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. JClin Immunol 2011, 31:315-322.
19. Hicks L.K., Woods A., Buckstein R., Mangel J., Pennell N., Zhang L., et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009, 43:701-708.
20. Kanbayashi Y., Nomura K., Fujimoto Y., Yamashita M., Ohshiro M., Okamoto K., et al. Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol 2009, 82:26-30.
21. Hansen D.A., Robbins B.A., Bylund D.J., Piro L.D., Saven A., Ellison D.J. Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia. Am J Clin Pathol 1994, 102:580-585.
22. Lim S.H., Esler W.V., Zhang Y., Zhang J., Periman P.O., Burris C., et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leukemia Lymphoma 2008, 49:152-153.
23. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
24. Bayrakci B., Ersoy F., Sanal O., Kilic S., Metin A., Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 2005, 47:239-246.
25. van Vollenhoven R.F., Emery P., Bingham C.O., Keystone E.C., Fleischmann R.M., Furst D.E., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013, 72:1496-1502.
26. Holle J.U., Dubrau C., Herlyn K., Heller M., Ambrosch P., Noelle B., et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012, 71:327-333.
27. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sanchez-Menendez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012, 64:3770-3778.
28. Compagno N., Cinetto F., Semenzato G., Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica 2014, 99:1101-1106.
29. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
30. Bingham C.O., Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
31. Buch M.H., Smolen J.S., Betteridge N., Breedveld F.C., Burmester G., Dorner T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
32. Roberts Darren M., Jones Rachel B., Smith Rona M., Alberici Federico, Kumaratne Dinakantha S., Burns Stella, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2014, 57:60-65. 10.1016/j.jaut.2014.11.009.